Loading

Physician Newsletter

New PET Rule for Medicare and Medicaid Patients

On June 11, 2013, the Centers for Medicare and Medicaid Services (CMS) issued a final decision memorandum on Positron Emission Tomography (PET) for Solid Tumors.
> Read More

Dr. Kiefer Now Seeing Patients at Palmer

Gauri Kiefer, MD, is now seeing patients at Arnold Palmer Medical Oncology, a partnership of Excela Health and UPMC CancerCenter, in Greensburg. > Read More

2013 San Antonio Breast Cancer Symposium – Update of Activities

On Dec. 11, 2013, Atilla Soran, MD, breast surgical oncologist at Magee, was one of 18 UPMC CancerCenter oncologists to present at the 2013 San Antonio Breast Cancer Symposium. > Read More

UPMC Shadyside Radiosurgery Program Expands

The Stereotactic Radiosurgery Program at UPMC CancerCenter is enhancing treatment delivery for an expanding number of patients with the addition of the CyberKnife® M6™ System at Mary Hillman Jennings Radiation Oncology Center at UPMC Shadyside.
> Read More

Now Available – Ra223 Xofigo® for Prostate Cancer

Four UPMC CancerCenter radiation oncology sites are now accepting patients who are candidates for Ra223 Xofigo®, a newly FDA-approved radiopharmaceutical for the treatment of patients with castration-resistant prostate cancer, symptomatic bones metastases, and no known visceral metastatic disease. > Read More

New UPMC CancerCenter at UPMC Altoona

UPMC Altoona's radiation oncology practice is now part of the UPMC CancerCenter network. > Read More

New Chronic GVHD and Long-Term Follow Up Program

The UPMC CancerCenter Stem Cell Transplant Program has launched the Chronic Graft Versus Host Disease (GVHD) and Long-Term Follow Up Program for patients who have received a stem cell transplant. > Read More

Consolidated Services at UPMC Natrona Heights

UPMC CancerCenter has consolidated its radiation oncology practice at UPMC Natrona Heights. > Read More

Clinical Trials at UPCI and UPMC CancerCenter

UPMC CancerCenter currently has 131 clinical trials open for accrual. > Read More

Upcoming Conferences

Two conferences are available in April on the UPMC Shadyside campus. Each activity has been approved for AMA PRA Category 1 Credit(s)™. There also is a Stereotactic Radiosurgery conference in May in Minneapolis, where UPMC CancerCenter is hosting the Meet and Greet Breakfast and two breakout sessions on SRS/SBRT for head and neck cancers and gastrointestinal cancers. This conference has been approved for up to a maximum of 26.5 AMA PRA Category 1 Credit(s)™. > Read More

Welcome, New Faculty

Welcome to our newest physicians and faculty. > Read More


New PET Rule for Medicare and Medicaid Patients

PET-CTOn June 11, 2013, the Centers for Medicare and Medicaid Services (CMS) issued a final decision memorandum on Positron Emission Tomography (PET) for Solid Tumors.1

This decision memorandum was in response to the request of the National Oncologic PET Registry (NOPR) to lift the requirement for Coverage with Evidence Development (CED) on subsequent PET scans for oncologic purposes.

There were three specific elements of this decision:

  1. CMS is ending the requirement for CED for FDG PET for oncologic indications. This removes the requirement for prospective data collection by the NOPR for those cancers or cancer types that had been covered under CED.
  2. CMS has determined that:
  3. CMS will nationally cover FDG PET when used to guide subsequent anti-tumor treatment strategy of prostate cancer.

Resources available:

The following table is taken from Appendix C of the National Coverage Determination2 for FDG PET for oncologic conditions effective June 11, 2013:

Tumor Type Initial Treatment Strategy Subsequent Treatment Strategy
Colorectal Covered Covered
Esophagus Covered Covered
Head and Neck (not thyroid or CNS) Covered Covered
Lymphoma Covered Covered
Non-small cell lung Covered Covered
Ovary Covered Covered
Brain Covered Covered
Cervix Covered with exceptions* Covered
Small cell lung Covered Covered
Soft tissue sarcoma Covered Covered
Pancreas Covered Covered
Testes Covered Covered
Prostate Non-covered Covered
Thyroid Covered Covered
Breast (male and female) Covered with exceptions* Covered
Melanoma Covered with exceptions* Covered
All other solid tumors Covered Covered
Myeloma Covered Covered
All other cancers not listed Covered Covered

Initial Treatment Strategy (ITS) was formerly diagnosis and initial staging. One PET scan is nationally covered by Medicare with additional scans covered at the discretion of each local Medicare Administrative Contractor.

Subsequent Treatment Strategy (STS) was formerly treatment monitoring, restaging and detection of suspected recurrence. Three PET scans are covered by Medicare with additional scans covered at the discretion of each local Medicare Administrative Contractor.

* Cervix: Nationally non-covered for the initial diagnosis of cervical cancer related to initial anti-tumor treatment strategy. All other indications for initial anti-tumor treatment strategy for cervical cancer are nationally covered.

* Breast: Nationally non-covered for initial diagnosis and/or staging of axillary lymph nodes. Nationally covered for initial staging of metastatic disease. All other indications for initial anti-tumor treatment strategy for breast cancer are nationally covered.

* Melanoma: Nationally non-covered for initial staging of regional lymph nodes. All other indications for initial anti-tumor treatment strategy for melanoma are nationally covered.

Reference:

Back to Top


Dr. Kiefer Now Seeing Patients at Palmer

Gauri Kiefer, MDGauri Kiefer, MD, is now seeing patients at Arnold Palmer Medical Oncology, a partnership of Excela Health and UPMC CancerCenter, in Greensburg. Dr. Kiefer specializes in internal medicine and subspecializes in medical oncology.

She joins Terry Evans, MD; Matthew Sulecki, MD; and Franklin Viverette, MD, to offer medical oncology and hematology services, including:

  • Interferon (IFN)
  • Interleukin
  • Colony stimulating factors (CSF)
  • Monoclonal antibodies (MoAb)
  • Chemotherapy administration
  • Clinical trials

For appointments, call 724-838-1900.

Back to Top


2013 San Antonio Breast Cancer Symposium – Update of Activities

Atilla Soran, MD

On Dec. 11, 2013, Atilla Soran, MD, breast surgical oncologist at Magee, was one of 18 UPMC CancerCenter oncologists to present at the 2013 San Antonio Breast Cancer Symposium. Learn about Dr. Soran's clinical trial that examines survival rates for surgical patients with advanced breast cancer.

On January 24, Barry Lembersky, MD, and Shannon Puhalla, MD, presented a comprehensive review of the most important presentations from the symposium to physicians and health care professionals. Also during the review session, the Arnold Palmer Cancer Center, a partnership of Excela Health and UPMC CancerCenter, was awarded the “B Cup,” recognizing the site as accruing the most breast cancer trials in 2013. The award was accepted by Franklin Viverette, MD, on behalf of Terry Evans, MD, Gauri Kiefer, MD, and Matthew Sulecki, MD.

Additional UPMC CancerCenter Poster Sessions

Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy:
Results of a secondary analysis of TBCRC 017

McGuire KP, De Los Santos JF, Cantor A, Forero A, Golshan M, Meric-Bernstam F, Horton JK, Amos KD, Hudis CA, Hylton NM, Meszoely IM, Nanda R, Hwang S. University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; University of Alabama at Birmingham, Birmingham, AL; Harvard Medical School, Boston, MA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Duke University Medical School, Durham, NC; University of North Carolina Chapel Hill, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California at San Francisco, San Francisco, CA; Vanderbilt Medical Center, Nashville, TN; University of Chicago, Chicago, IL; Duke University, Durham, NC.

Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy

Santa-Maria CA, Dantzer J, Li L, Skaar T, Oesterreich S, Rae JM, Zeruesenay D, Nguyen AT, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post W, Flockhart DA, Stearns V. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Indiana University School of Medicine; University of Pittsburgh Cancer Institute; University of Michigan Comprehensive Cancer Center; Johns Hopkins University School of Medicine. Cesar Augusto Santa-Maria is a recipient of an AACR Scholar-In-Training Award

cMethDNA is a quantitative circulating methylated DNA assay for detection of metastatic breast cancer and for monitoring response to therapy

Fackler MJ, Bujanda ZL, Umbricht C, Teo WW, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope LA, Wolff AC, Sukumar S. Johns Hopkins University School of Medicine, Baltimore, MD; Memorial Sloan-Kettering Cancer Center, NY, NY; Mayo Clinic, Rochester, MN; University of Pittsburgh Medical Center, Pittsburgh, PA; University of North Carolina, Chapel Hill, NC.

Lymphatic and pro-inflammatory candidate gene variations and breast-cancer related lymphedema

Fu MR, Axelrod D, Guth AA, Goldberg J, Li X, Cartwright F, Haber J, Conley Y. New York University, New York, NY; NYU School of Medicine, New York, NY; University of Pittsburgh, Pittsburgh, PA; NYU Cancer Center, New York, NY.

Intra-tumor heterogeneity affects multi-gene test prognostic risk stratification

Lee AV, Lin Y, Lin H-M, Cooper KL, Normolle DP, Brufsy AM, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ. University of Pittsburgh Cancer Institute, Pittsburgh, PA.

TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer

King TA, Lyman JP, Gonen M, Voci A, Boafo C, Hwang ES, Rugo HS, Alvarado M, Liu M, Boughey JC, Jacobs LK, Krontiras H, McGuire K, Storniolo AM, Nanda R, Golshan M, Isaacs C, Bijelic L, Meszoely IM, Van Poznak C, Babiera G, Norton L, Morrow M, Winer EP, Wolff AC, Hudis CA. Memorial Sloan-Kettering Cancer Center, New York, NY; Duke University Medical Center, Durham, NC; University of California San Francisco, San Francisco, CA; Mayo Clinic, Rochester, MN; John Hopkins Medical Institution, Baltimore, MD; University of Alabama At Birmingham, Birmingham, AL; University of Pittsburgh Medical Center, Pittsburgh, PA; Indiana University Simon Cancer Center, Indianapolis, IN; University of Chicago, Chicago, IL; Dana Farber Cancer Institute, Boston, MA; Georgetown University, Washington, DC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; Translational Breast Cancer Research Consortium.

HER2 copy number on FISH as a predictor of disease severity in HER2- breast cancer

Abedin S, Kruse M, Brufsky A, Bhargava R. University of Michigan Health System, Ann Arbor, MI; University of Pittsburgh Medical Center, Pittsburgh, PA.

The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer

Linden H, Kurland B, Link J, Novakova A, Chai X, Gadi V, Specht J, Hills D, Gralow J, Schubert E, Korde L, Peterson L, Doot R, Eary J, Shields A, Krohn K, Mankoff D. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; University of Pennsylvania, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA.

HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates

Linden H, Kurland B, Link J, Novakova A, Chai X, Specht J, Gadi V, Gralow J, Schubert E, Peterson L, Eary J, Shields A, Mankoff D, Krohn K. University of Washington, Seattle, WA; Fred Hutchison Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; University of Pennsylvania, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA.

Unique genetic, epigenetic, and transcriptomic changes in premenopausal breast cancer suggest novel strategies for therapy

Liao G, Hartmaier RJ, Luthra S, Chandran U, McGuire KP, Puhalla SL, Lee AV, Tseng GC, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh Cancer Institute, Magee Womens Research Institute, Pittsburgh, PA; University of Pittsburgh Cancer Institute, UPMC Cancer Center, Pittsburgh, PA.

Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic
HER2-positive breast cancer

Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Rege J, Cox D, Vahdat L. US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY.

Effect of doxorubicin and paclitaxel on adipose-derived stem cells and breast cancer cells: Can we incorporate chemotherapy into our
reconstructive strategies?

Tsuji W, Chung CW, McLaughlin MM, Valentin JE, Marra KG, Rubin JP. Adipose Stem Cell Center, University of Pittsburgh, Pittsburgh, PA.

Modeling breast cancer dormancy

Wheeler SE, Taylor DP, Clark AM, Borenstein JT, Ebrahimkhani MR, Inman W, Nguyen T, Pillai VC, Prantil-Baun R, Ulrich TA, Venkataramanan R, Lauffenburger DA, Griffith L, Stolz DB, Wells A. University of Pittsburgh, Pittsburgh, PA; The Charles Stark Draper Laboratory, Inc, Cambridge, MA; Massachusetts Institute of Technology, Cambridge, MA. Sarah E. Wheeler is a recipient of an AACR Scholar-In-Training Award

Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Chandran UR, Wang G, Dabbs DJ, Welm AL, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Utah, Salt Lake City, UT.

Treatment decisions and five year outcomes of the oncotype Dx test: An independent assessment

Bhargava R, Brufsky AM, Lembersky BC, Jankovic R, Puhalla SL, Oesterreich S, Lee A, Dabbs DJ. Magee-Women's Hospital of UPMC, Pittsburgh, PA, Uganda.

Risk of CNS relapse following adjuvant trastuzumab therapy – Updated literature-based meta-analysis

Mathew A, Brufsky AM. University of Pittsburgh Cancer Institute, Pittsburgh, PA

tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as
first-line treatment for triple-negative metastatic breast cancer

Yardley DA, Brufsky A, Conte P, Cortes J, Gl&0252 ck S, Nabholtz J-MA, O'Shaughnessy J, Li L, Barton D, Fandi A, Harbeck N. Sarah Canon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Padova, Padova, Italy; University Hospital Vall d'Hebron, Barcelona, Spain; University of Miami, Miami, FL; Centre de Lutte Contre le Cancer d'Auvergne, Clermont Ferrand, France; US Oncology, Dallas, TX; Celgene Corporation, Summit, NJ; Breast Center, University of Munich, Munich, Germany.

Back to Top


UPMC Shadyside Radiosurgery Program Expands

Cybernife® M6™The Stereotactic Radiosurgery Program at UPMC CancerCenter is enhancing treatment delivery for an expanding number of patients with the addition of the CyberKnife® M6™ System at Mary Hillman Jennings Radiation Oncology Center at UPMC Shadyside.

The CyberKnife M6 is the first system of its kind in western Pennsylvania designed to treat cancerous and non-cancerous tumors anywhere in the body, including the brain, head and neck, spine, lung, prostate, liver, and pancreas, and allows our clinicians to offer radiosurgery treatment to a number of patients once considered ineligible for radiosurgery.

The CyberKnife M6 System joins our already expansive array of radiation delivery platforms, including:

Learn more about stereotactic radiosurgery at UPMC CancerCenter.

For patient referrals, contact the SRS program at 855-SRS-FACT (777-3228) or radiosurgeryteam@upmc.edu.

Back to Top


Now Available - Ra223 Xofigo® for Prostate Cancer

drugsFour UPMC CancerCenter radiation oncology sites are now accepting patients who are candidates for Ra223 Xofigo®, a newly FDA-approved radiopharmaceutical for the treatment of patients with castration-resistant prostate cancer, symptomatic bones metastases, and no known visceral metastatic disease.

Sites offering Xofigo:

For Xofigo referrals, contact the above radiation oncology sites directly.

Back to Top


New UPMC CancerCenter at UPMC Altoona

UPMC AltoonaUPMC Altoona's radiation oncology practice is now part of the UPMC CancerCenter network.

UPMC CancerCenter welcomes Jack D. Schocker, MD, radiation oncologist who has practiced in the Altoona region for more than 31 years. Dr. Schocker and staff utilize advanced treatment technology, including Elekta's newest linear accelerator, Elekta Infinity™.

Other services and technologies include:

Appointments can be made by calling 814-889-2400 or 800-870-4660.

Back to Top


New Chronic GVHD and Long-Term Follow Up Program

Chronic graft versus host disease (GVHD) can be a common complication of a stem cell transplant. Symptoms may not appear until months or years following a transplant, but they can manifest quickly and affect all organs of the body.

The UPMC CancerCenter Stem Cell Transplant Program has launched the Chronic Graft Versus Host Disease (GVHD) and Long-Term Follow Up Program for patients who have received a stem cell transplant. The program is spearheaded by Annie Im, MD, assistant professor of medicine, and Mounzer Agha, MD, director of the Stem Cell Transplant Program.

In addition to their regular post-transplant oncology appointments, patients will see a GVHD specialist every three to six months initially, who will survey for and manage possible complications from stem cell transplant.

”Our goal is to improve the quality of care for stem cell patients,” says Dr. Im. “The GVHD Program provides an added care component that can make a difference in identifying the early signs of GVHD so we can treat it accordingly when it's more manageable. In addition, we perform transplant-specific follow up and surveillance for patients, given that they have risk factors that are unique to transplant patients.”

Any patient who has ever received a stem cell transplant can be referred to the program by calling 412-692-4724 or the Mario Lemieux Center for Blood Cancers at 412-864-6600.

Learn more about the Chronic Graft Versus Host Disease (GVHD) and Long-Term Follow Up Program.

Back to Top


Consolidated Services at UPMC Natrona Heights

UPMC CancerCenter, Natrona HeightsUPMC CancerCenter has consolidated its radiation oncology practice at UPMC Natrona Heights. Colin Champ, MD, now sees patients here for initial consults and follow-up visits on Tuesdays and Fridays from 8 a.m. to 4 p.m. Call 724-230-3030 for appointments.

Patients may be referred to UPMC CancerCenter Radiation Oncology at UPMC St. Margaret where Ryan Smith, MD, and Dr. Champ provide comprehensive radiation oncology treatment, including:

Contact UPMC CancerCenter Radiation Oncology at UPMC St. Margaret at 412-784-4900.

Back to Top


Clinical Trials at UPCI and UPMC CancerCenter

UPMC CancerCenter currently has 131 clinical trials open for accrual. Check out the four trials featured below, or search additional clinical trials.

Featured in this edition:

Four of our current clinical trials are listed below.

Back to Top


Upcoming Conferences

Two conferences are available in April on the UPMC Shadyside campus. Each activity has been approved for AMA PRA Category 1 Credit(s)™

The following conference is available in May and is approved for up to a maximum of 26.5 AMA PRA Category 1 Credit(s)™.

The University of Pittsburgh is an affirmative action, equal opportunity institution.

Back to Top


Welcome, New Faculty

Welcome to our newest physicians and faculty:

Magee-Womens Cancer Program

Madeleine Courtney-BrooksMadeleine Courtney-Brooks, MD, MPH, is a gynecologic oncologist and assistant professor of gynecologic oncology. She specializes in minimally-invasive gynecologic oncology surgery and has research interests in optimizing gynecologic oncology care for elderly patients and quality of life at the end of life care for gynecologic oncology patients.

Marilyn HuangMarilyn Huang, MD, is a gynecologic oncologist and assistant professor in the Division of Gynecology Oncology. She specializes in all gynecologic malignancies and is interested in hereditary gynecologic cancers, minimally-invasive surgery, and Phase I clinical trials.

UPMC Presbyterian

Melissa HoggMelissa Hogg, MD, is a surgical oncologist specializing in gastrointestinal surgical oncology with a focus in minimally-invasive treatment of benign and malignant diseases of the stomach, bile duct, and pancreas.

Javier SalgadoJavier Salgado, MD, is a colorectal surgeon in the Division of Colon and Rectal Surgery. He specializes in the treatment of colon and rectal cancer, inflammatory bowel disease (IBD), and other diseases of the colon and rectum. He also participates in clinical research involving the treatment of colon and rectal cancer and IBD.

Butler Health System Medical Oncology

Rushir J. ChoksiRushir J. Choksi, MD, is a medical oncologist and sees all medical oncology and hematology cases.

UPMC CancerCenter Medical Oncology, Upper St. Clair

Robert VanderWeeleRobert VanderWeele, MD, MS, is a hematologist/medical oncologist specializing in cytopenias, bleeding and clotting disorders, leukemia, lymphoma, myeloma, GI malignancies, breast cancer, lung cancer, and prostate cancer.

UPMC CancerCenter Medical Oncology, Monroeville

Rajesh SehgalRajesh Sehgal, MBBS, MD, FACP, is a hematologist/medical oncologist at UPMC CancerCenter. He specializes in the treatment of solid tumors, including breast cancer, colon cancer, and lung cancer, and blood disorders, including bleeding problems and coagulation abnormalities.

Hillman Cancer Center

Laura DeCastroLaura DeCastro, MD, is director of clinical translational research for the Adult Sickle Cell Center of Excellence, clinical director of the Benign Hematology Program at UPMC, and director of benign hematology for the Institute for Transfusion Medicine and UPMC CancerCenter. Her major research interests include investigating the impact of sickle cell disease on end-organ damage, investigating the psychosocial issues relating to sickle cell disease, and developing novel treatments for sickle cell disease.

Annie ImAnnie Im, MD, is an assistant professor of medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing and conducting research in hematologic malignancies, drug development, stem cell transplantation, and graft-versus-host-disease. In addition, Dr. Im specializes in the long term follow up of stem cell transplant recipients and the chronic graft-versus-host-disease clinic.

Gregory J. KatoGregory J. Kato, MD, is professor of medicine, director of the Adult Sickle Cell Center of Excellence for the UPP Division of Hematology-Oncology, and director of the Vascular Medicine Institute/Institute for Transfusion Medicine Sickle Cell Center of Excellence. He treats nonmalignant hematology concerns in adults and specializes in adult and pediatric sickle cell disease. Dr. Kato's translational research focuses on the role of iron overload and angiogenic factors on pulmonary hypertension in sickle cell disease. In addition, Dr. Kato is a leader in early phase clinical trials in sickle cell disease.

Alison SehgalAlison Sehgal, MD, is an assistant professor of medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing in allogeneic and autologous stem cell transplant, lymphoma, leukemia, and multiple myeloma. Dr. Sehgal is conducting research in stem cell transplant and drug development for hematologic malignancies.

UPMC CancerCenter Radiation Oncology at UPMC Altoona

Jack D. SchockerJack D. Schocker, MD, is a radiation oncologist and sees all general radiation oncology cases.

UPMC CancerCenter Radiation Oncology
at UPMC St. Margaret

Colin ChampColin Champ, MD, is a radiation oncologist who treats all malignancies and has a special research interest in the treatment of breast cancer, CNS malignancies, and clinical nutrition and exercise relating to cancer treatment. Dr. Champ also sees patients for consultations and initial follow up visits at UPMC CancerCenter Radiation Oncology, Natrona Heights.

Mary Hillman Jennings Radiation Oncology Center
at UPMC Shadyside

David A. ClumpDavid A. Clump II, MD, PhD, is a radiation oncologist specializing in head and neck malignancies and stereotactic radiosurgery.

UPMC/St. Clair Hospital Cancer Center

Felicia SneadFelicia Snead, MD, is a radiation oncologist specializing in breast, central nervous system, and gastrointestinal cancers, and general radiation oncology.

UPMC CancerCenter Radiation Oncology UPMC Northwest

Joseph WangJoseph Wang, MD, is a radiation oncologist specializing in the treatment of all cancers, intensity-modulated radiation therapy, and image-guided radiation therapy.

Back to Top